Alk

LONDON, June 7, 2010 - Data published at the European Allergy, Asthma & Clinical Immunology (EAACI) congress in London today documents that GRAZAX(R) is the only allergy immunotherapy tablet (AIT) to show sustained disease control 2 years after treatment completion.